Clinical Trials in the USA / NCT07161843
Starting soon
Phase 2/3
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
NCT07161843 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Acute Renal Failure (ARF)Acute Tubular Necrosis
Investigational drug(s) / intervention(s)
QRX-3: Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Study summary
Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure
Eligibility
Inclusion Criteria:
* Hospitalized patients
* presence of Acute renal failure
* Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \>2%
* willingness to participate
Exclusion Criteria:
High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status
Primary outcome measure(s)
- Rate of change in creatinine glomerular filtration rate — 28 days
compare the outcome effect of added QRX-3 drug to placebo in addition to standard therapy on the rate of change from baseline of creatinine GFR in ATN patients
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Neukidney Inc | Rosharon | Texas |
More Ebima Clifford Okundaye trials in the USA
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07161843 on ClinicalTrials.gov ↗ ← All trials in the USA